Back to News
Market Impact: 0.38
FDA Expands Lilly's Olumiant Approval To Adolescents With Severe Alopecia Areata
Source: Nasdaq
Healthcare & BiotechProduct Launches
The FDA approved Eli Lilly's Olumiant (baricitinib) to treat severe alopecia areata in pediatric patients aged 12 and older. The decision expands Olumiant's approved use beyond adults, opening an additional patient population and supporting Lilly's dermatology franchise.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
LLY0.82
More News
- Here are the 4 big things we're watching in the stock market in the week ahead
- Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
- Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
- OpenAI, Anthropic CEOs called to appear at Australian AI probe
- Why Meta Platforms Stock Jumped 13% This Week
- Australia summons OpenAI and Anthropic CEOs to appear at AI inquiry
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- AI Software for Buy-Side Teams: Build the Research Stack